Biocon Limited Share Price

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Market Closed - NSE India S.E. 12:43:47 26/04/2024 BST 5-day change 1st Jan Change
306.4 INR +5.06% Intraday chart for Biocon Limited +17.10% +22.73%

Financials

Sales 2024 * 145B 1.74B 139B Sales 2025 * 166B 1.99B 159B Capitalization 366B 4.39B 351B
Net income 2024 * 9.49B 114M 9.11B Net income 2025 * 9.3B 111M 8.93B EV / Sales 2024 * 3.48 x
Net Debt 2024 * 139B 1.67B 134B Net Debt 2025 * 143B 1.71B 137B EV / Sales 2025 * 3.07 x
P/E ratio 2024 *
38.5 x
P/E ratio 2025 *
42.9 x
Employees 16,545
Yield 2024 *
0.43%
Yield 2025 *
0.47%
Free-Float 37.3%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.06%
1 week+17.10%
Current month+15.99%
1 month+18.90%
3 months+18.44%
6 months+37.96%
Current year+22.73%
More quotes
1 week
262.15
Extreme 262.15
313.40
1 month
259.20
Extreme 259.2
313.40
Current year
244.55
Extreme 244.55
313.40
1 year
217.50
Extreme 217.5
313.40
3 years
191.55
Extreme 191.55
420.25
5 years
191.55
Extreme 191.55
487.75
10 years
65.88
Extreme 65.8833
487.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 30/04/13
Chief Executive Officer 65 11/12/22
Chairman 71 28/11/78
Members of the board TitleAgeSince
Chairman 71 28/11/78
Director/Board Member 69 31/12/99
Director/Board Member 60 26/07/18
More insiders
Date Price Change Volume
26/04/24 306.4 +5.06% 45,364,970
25/04/24 291.6 +0.71% 7,923,803
24/04/24 289.6 +3.37% 24,783,740
23/04/24 280.2 +3.32% 10,392,190
22/04/24 271.2 +3.63% 8,601,670

Delayed Quote NSE India S.E., April 26, 2024 at 12:43 pm

More quotes
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
306.4 INR
Average target price
279.1 INR
Spread / Average Target
-8.91%
Consensus
  1. Stock Market
  2. Equities
  3. BIOCON Stock